Back to Search
Start Over
SGLT6 - A pharmacological target for the treatment of obesity?
- Source :
-
Adipocyte [Adipocyte] 2018; Vol. 7 (4), pp. 277-284. Date of Electronic Publication: 2018 Oct 11. - Publication Year :
- 2018
-
Abstract
- Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.
- Subjects :
- Animals
Anti-Obesity Agents pharmacokinetics
Anti-Obesity Agents therapeutic use
Caco-2 Cells
Food Preferences drug effects
Glucose metabolism
HEK293 Cells
Humans
Inositol metabolism
Male
Mice
Mice, Inbred C57BL
Molecular Targeted Therapy
Anti-Obesity Agents pharmacology
Heat-Shock Proteins antagonists & inhibitors
Heat-Shock Proteins metabolism
Obesity drug therapy
Obesity metabolism
Symporters antagonists & inhibitors
Symporters metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 2162-397X
- Volume :
- 7
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Adipocyte
- Publication Type :
- Academic Journal
- Accession number :
- 30161013
- Full Text :
- https://doi.org/10.1080/21623945.2018.1516098